Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02950805 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis
A Phase 1 study of Pulmonary/Respiratory Diseases, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 3
- Study locations
NCT02950805 is a Phase 1 study of Pulmonary/Respiratory Diseases that has completed, run by AstraZeneca. The registered enrollment target is 9 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT02950805, a Phase 1 study of Pulmonary/Respiratory Diseases, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will assess the effect of inhaled AZD5634 on Mucociliary clearance (MCC) in patients with Cystic fibrosis (CF) after single-dose administration.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD5634
Study Locations (3)
Alabama
- Research Site - Birmingham
Maryland
- Research Site - Baltimore
North Carolina
- Research Site - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-05-30 |
| Est. Completion | 2018-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02950805
The ClinicalTrials.gov registry entry for NCT02950805 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary/Respiratory Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02950805 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02950805 about?
NCT02950805 is a clinical study titled "A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis". This study will assess the effect of inhaled AZD5634 on Mucociliary clearance (MCC) in patients with Cystic fibrosis (CF) after single-dose administration.
What is the current status of trial NCT02950805?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2017-05-30. Estimated completion is 2018-04-12.
What conditions does trial NCT02950805 study?
This clinical trial studies the following conditions: Pulmonary/Respiratory Diseases.
What interventions are being tested in trial NCT02950805?
The interventions under investigation include: Placebo (DRUG), AZD5634 (DRUG).
Who is sponsoring clinical trial NCT02950805?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02950805 being conducted?
This trial has 3 study locations across Alabama, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.